Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.12.19
Views: 172
Rating:

Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA

Dr Courtney DiNardo speaks to ecancer at the ASH 2019 meeting in Orlando about enasidenib plus azacitidine when treating older patients with AML.

The study looked at enasidenib plus azacitidine vs with just azacitidine in newly diagnosed AML patients with IDH2 mutations.

Dr DiNardo explains the positive results and that the combination improves response rates without concerning toxicity.

Related videos

follow us

SIOG metastatic renal cell carcinoma


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation